Omacetaxine News and Research

RSS
Chemistry researchers patent new method for making anti-leukemia compounds

Chemistry researchers patent new method for making anti-leukemia compounds

Drug combination targets pre-leukemia stem cells

Drug combination targets pre-leukemia stem cells

Teva's SYNRIBO for injection receives FDA approval for home administration

Teva's SYNRIBO for injection receives FDA approval for home administration

FDA grants full approval of SYNRIBO for injection

FDA grants full approval of SYNRIBO for injection

Iclusig gets FDA approval for two rare blood and bone marrow diseases

Iclusig gets FDA approval for two rare blood and bone marrow diseases

Pfizer receives FDA approval for Synribo to treat chronic myelogenous leukemia

Pfizer receives FDA approval for Synribo to treat chronic myelogenous leukemia

Cephalon intends to make takeover bid for ChemGenex

Cephalon intends to make takeover bid for ChemGenex

Cephalon signs convertible note subscription agreement with ChemGenex Pharmaceuticals

Cephalon signs convertible note subscription agreement with ChemGenex Pharmaceuticals

ChemGenex agrees with FDA on potential regulatory path to progress OMAPRO for CML

ChemGenex agrees with FDA on potential regulatory path to progress OMAPRO for CML

ChemGenex reports positive safety findings from two OMAPRO clinical trials at ASCO 2010

ChemGenex reports positive safety findings from two OMAPRO clinical trials at ASCO 2010

FDA issues complete response letter regarding the NDA for OMAPRO

FDA issues complete response letter regarding the NDA for OMAPRO

ChemGenex shares falter as FDA requests more data on new leukemia drug

ChemGenex shares falter as FDA requests more data on new leukemia drug

FDA's ODAC voted to review T315I mutation prior to approval of OMAPRO

FDA's ODAC voted to review T315I mutation prior to approval of OMAPRO

ChemGenex Pharmaceuticals' OMAPRO review: FDA reschedules ODAC meeting to 22 March, 2010

ChemGenex Pharmaceuticals' OMAPRO review: FDA reschedules ODAC meeting to 22 March, 2010

ODAC to conduct public advisory meeting to review ChemGenex Pharmaceuticals’ NDA for Omapro

ODAC to conduct public advisory meeting to review ChemGenex Pharmaceuticals’ NDA for Omapro

ChemGenex Pharmaceuticals and Hospira enter into exclusive agreement

ChemGenex Pharmaceuticals and Hospira enter into exclusive agreement

Phase II clinical trial results reveal positive effects of omacetaxine against CML

Phase II clinical trial results reveal positive effects of omacetaxine against CML

ChemGenex Pharmaceuticals presents clinical results of Omapro drug at ASH meeting

ChemGenex Pharmaceuticals presents clinical results of Omapro drug at ASH meeting

New treatment options for leukemia and myeloproliferative disorders introduced

New treatment options for leukemia and myeloproliferative disorders introduced

ChemGenex Pharmaceuticals to present updated clinical data from its clinical trials with Omapro

ChemGenex Pharmaceuticals to present updated clinical data from its clinical trials with Omapro